Review

Genetics, Structure, Transmission, Epidemiology, Immune response, and Vaccine Efficacies of the SARS-CoV-2 Delta variant: A Comprehensive Review

*Running Title: COVID-19 Delta variant comprehensive review*

Han. Li1†, Chelsea-Jane Arcalas1†, Junmin Song2†, Masoud Rahmati3†, Seoyeon Park4, Ai Koyanagi5,6, Seung Won Lee7,8, Dong Keon Yon9,10, Jae Il Shin11, Lee Smith12

1 University of Florida College of Medicine, Gainesville, FL 32610, USA

2 Keimyung University School of Medicine, Daegu, Republic of Korea

3 Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran

4 Yonsei University College of Medicine, Seoul, Republic of Korea

5 Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain

6 ICREA (Catalan Institution for Research and Advanced Studies), Barcelona, Spain

7 Department of Data Science, Sejong University College of Software Convergence, Seoul, Republic of Korea

8 Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

9 Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, Republic of Korea

10 Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea

11 Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.

12 Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, UK

† These authors contributed equally

**Corresponding Author:**

Jae Il Shin, M.D., Ph.D.

Address: 50 Yonsei-ro, Seodaemun-gu, C.P.O. Box 8044, Department of Pediatrics, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea

Tel: +82-2-2228-2050; Fax: +82-2-393-9118; E-mail: [shinji@yuhs.ac](mailto:shinji@yuhs.ac)

**Word Count: 3,227**

**Declarations**

**Data availability statement**: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Funding statement:** No financial support was provided for research conduct and/or article preparation.

**Conflict of interest disclosure**: No conflict of interest declared

**Ethics approval statement**: Not applicable

**Patient consent statement**: Not applicable

**Permission to reproduce material from other sources**: Not applicable

**Acknowledgment:** None

**Author contribution statement:**

Han. Li: Conceptualization, Methodology, Investigation, Writing – Original Draft, Chelsea-Jane Arcalas: Conceptualization, Methodology, Investigation, Writing – Original Draft, Junmin Song: Writing – Original Draft, Writing – Review and Editing, Masoud Rahmati: Writing – Review and Editing, Seoyeon Park: Writing – Review and Editing, Ai Koyanagi: Writing – Review and Editing, Seung Won Lee: Writing – Review and Editing, Dong Keon Yon: Writing – Review and Editing, Jae Il Shin: Conceptualization, Methodology, Investigation, Lee Smith: Writing – Review and Editing

**Summary**

The SARS-CoV-2 Delta variant (B.1.617.2) was the predominant variant behind the surges of COVID-19 in the United States, Europe, and India in the second half of 2021. The information available regarding the defining mutations and their effects on the structure, transmission, and vaccine efficacy of SARS-CoV-2 is constantly evolving. With waning vaccine immunity and relaxation of social distancing policies across the globe driving the increased spread of the Delta variant, there is a great need for a resource aggregating the most recent information for clinicians and researchers concerning the Delta variant. Accordingly, this narrative review comprehensively reviews the genetics, structure, epidemiology, clinical course, and vaccine efficacy of the Delta variant. Comparison with the omicron variant is also discussed. The Delta variant is defined by 15 mutations in the Spike protein, most of which increase affinity for the ACE-2 receptor or enhance immune escape. The Delta variant causes similar symptoms to prototypical COVID-19, but it is more likely to be severe, with a greater inflammatory phenotype and viral load. The reproduction number is estimated to be approximately twice the prototypical strains during the early pandemic, and numerous breakthrough infections have been reported. Despite studies demonstrating breakthrough infection and reduced antibody neutralization, full vaccination effectively reduces the likelihood of severe illness and hospitalization.

**Keywords:** COVID-19; SARS-CoV-2; Delta variant; epidemiology; public health; virology;

**List of Abbreviations:** COVID-19, coronavirus disease of 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ACE-2, angiotensin-converting enzyme 2; CI, confidence interval, RBD, receptor binding domain; HR, Hazard Ratio; aOR, adjusted odds ratio;

Introduction

As of 1st of March 2022, SARS-CoV-2 has infected 437,693,348 cases and 5,978,017 deaths.[1] Complicating epidemiological control of the pandemic is the evolution of new variants with global transmission, which often have increased infectivity and immune evasion. An early dominant variant was D614G, which increased transmission due to an amino acid substitution in its Spike protein.[2] Subsequently, the Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Gamma (P.1), and Omicron (B.1.1.529) variants have emerged as variants of concern by the WHO for their infectivity, evade detection, evade immunity, and reduce therapeutic effectiveness.[3]First identified in India in December 2020 as a sublineage of the B.1.617 variant, B.1.617.2 is particularly concerning for its rapid transmission among unvaccinated populations, as well as reports of breakthrough transmission in vaccinated individuals.[4] The Delta variant had emerged as the dominant contagion in the United States, United Kingdom, India, and Israel.[5] B.1.617.2 is up to 50% more transmissible than the B.1.1.7 variant, responsible for the infection waves in India and the UK.[6] Additionally, many countries have low vaccination acceptance due to their economic or cultural beliefs, which may have increased susceptibility to SARS-CoV-2 and its mutation.[7, 8]

Underlying its increased transmission are several amino acid substitutions in the Spike protein, allowing for enhanced affinity for the angiotensin-converting enzyme 2 (ACE2) receptor, immune evasion, and resistance to degradation.[6] The variants of concern all contain mutations that enhance receptor binding affinity for the ACE2 receptor.[9] The first variant of concern, the Alpha variant, contains eight mutations in the Spike protein, of which N501Y increases affinity for the ACE2 receptor. This variant tends to have higher mortality than its ancestor lineages. For the alpha variant, the BNT162b2 vaccine effectively reduces the likelihood of infection, reduces symptomatic infection, and reduces secondary transmission once infected.[10] The Beta variant has three mutations that increase binding affinity for the ACE2 receptor and also demonstrates a comparable reduction in efficacy following two doses of the mRNA-1273 vaccine to wildtype SARS-CoV-2.[11] The Gamma variant hosts three affinity-boosting mutations in the Spike protein. Evidence concerning breakthrough infection by the Gamma variant is scarce. One small case series from French Guiana reported similar infection rates between vaccinated and unvaccinated miners.[12] The Omicron variant has more than 30 mutations in the Spike protein, which greatly increases the transmission and reinfection rates.[13] Although breakthrough infection and increased infectivity have been reported for all variants of concern, the Delta variant arouses particular concern because of 1) its emergence as a dominant strain in multiple waves of infection globally, even in the presence of other variants of concern and variants of interest;[9] and 2) early reports specifying a potentially high proportion of breakthrough infection.[14, 15]

Although individual studies have reported genetics, viral structure, clinical course, immune response, epidemiology, detection, and vaccine efficacy associated with the Delta variant, no comprehensive review of this kind has previously been reported. Despite the rapidly evolving and growing threat of Delta variant transmission, there exist few resources conglomerating the available information for clinicians and epidemiologists.

Accordingly, we performed a comprehensive review of the Delta variant genetics, structure, clinical course, immune response, epidemiology, transmission, vaccine efficacy, and breakthrough infection.

*Genetics*

Of the variants of concern, the Alpha variant was the first to emerge, described in the United Kingdom in December 2020. The Beta and Delta variants followed in South Africa and Maharashtra, India, respectively, in December 2020, the Gamma variant emerged in Brazil in January 2021, and the Omicron variant was reported in November 2021 in South Africa. The Delta variant is a sublineage of variant B.1.617 out of three in total (B.1.617.1, B.1.617.2, B.1.617.3).

The precise number of mutations that distinguish the Delta strain is constantly evolving. The genetic diversity of the Delta variant amongst countries is greater than the Alpha variant, but to date, there are 15 defining mutations in the Spike protein that increase virulence: T19R, V70F\*, T95I, G142D, E156del, F157del, R158G, A222V\*, W258L\*, K417N\*, L452R, T478K, D614G, P681R, and D950N (\* the mutation was detected in some sequences but not in all).[16, 17] Several mutations (V70F, T95I, G142D, A222V, W258L, K417N) are present at higher frequencies in the Delta plus variant, a descendent of the Delta variant. However, since distinguishing these variants was beyond the scope of this paper, these mutations are all discussed in the context of the Delta variant. Three of these (K417N\*, L452R, T478K) are within the ACE2 receptor binding domain (RBD).[18] At least seven other structural mutations in the viral life cycle-associated membrane (I82T), nucleocapsid (R203M, D377Y), NS3 (S26L), and NS7a (V82a, T120l) are specific to the Delta variant.[17] D614G, as the defining mutation in the ancestor dominant variant, is present in all variants of concern and their sublineages. The other variants of concern do not share any identical amino acid substitutions with Delta (except D614G) but do share some amino acid substitutional positions. The Alpha variant has a P681H substitution, as opposed to the P681R of Delta, and both Beta and Gamma have substitutions at the K417 position.[19]

Figure 1 summarizes the unique and shared mutations of all sublineages of the B.1.617 variant. The Delta variant parent lineage (B.1.617) is defined by G142D, L452R, D614G, and P681R, and these four mutations are found in all its branching sublineages. Unlike the Delta variant, B.1.617.1 has the unique mutations E154K and Q107H. B.1.617.3 additionally shares T19R and D950N with B.1.617.2. Both B.1.617.1 and B.1.617.3 possess an E484Q, which is not present in the Delta variant.[20] Despite the shared mutations encouraging transmissibility between all B.1.617 sublineages, only B.1.617.2 remains a dominant variant within Europe. Such differences in transmissibility may have resulted from the synergism in the B.1.617.2 unique mutations to increase cell entry and immune evasion.

*Structure*

The SARS-CoV-2 genome encodes 26 proteins. The four structural proteins include the Spike, Membrane, Nucleocapsid, and Envelope proteins. There are 16 non-structural proteins, NSP1 to NSP16, and six accessory proteins (NS3, NS6, NS7a, NS7b, NS8, and ORF10).[17] The Spike protein mediates SARS-CoV-2 cell entry and is a trimer with an S1 subunit that contains the RBD and an S2 subunit that contains peptides mediating cell fusion. The S protein is activated by cleavage of the S1/S2 site by host transmembrane protease serine 2 (TMPRSS2).[21]

Amino acids present at 438 to 506, a part of RBD, are responsible for higher virus transmission, infection, and immune escape.[22, 23] The most well-studied mutations currently include D614G, L452R, T478K, and P681R, located in the RBD or near the S1/S2 cleavage site. The D614G spike mutation significantly increases viral entry efficiency by a proposed mechanism that allows the Spike protein to adopt a more open conformation to bind ACE2.[24] Mutations in the RBD also drive a more positive electrostatic potential, further increasing affinity for the negatively charged ACE2 receptor.[25] Out of the RBD mutations, L452R and K417N allow immune escape. L452R facilitated neutralization escape from 14 of 34 monoclonal antibodies in one study.[26] K417N decreases ACE2 receptor binding but increases immune escape.[27] T478K increases ACE2 binding by further polarizing the RBD toward a positive electrostatic potential, which drives greater interaction with the negatively charged ACE2.[28] P681R, the closest substitution to the S1/S2 cleavage site, increases furin-mediated S cleavage by enhancing basicity and furin interaction.[29] In the N-terminal domain, T19R, E156del, F157del, and W258L encourage antibody escape, while V70F increases S1/S2 cleavage.[30-33] Other mutations concentrated in the N-terminal domain and the S2 subunit have, to the best of our knowledge, as of yet, unclear effects on viral function. Table 1 summarizes the mutations unique to the Delta variant, their locations in the viral genome, and their proposed effects on structure and function.[24-35]

*Clinical course and Immune Response*

The Delta variant causes a greater rate of severe infection. In a cohort study in England with 43,338 SARS-CoV-2 positive patients, the Delta variant was associated with greater frequencies of hospital admission (adjusted HR 2.26) and combined hospital admission or visits to the emergency department (adjusted HR 1.45).[36] The EAVE II study in Scotland also showed that patients with the Delta variant were more likely to be hospitalized within 14 days compared to patients with the alpha variant (HR 1.85).[37] Combined surveillance and single-center study in Singapore demonstrated similar findings that the B.1.617.2 variant is associated with pneumonia (aOR 1.88), oxygen requirement, ICU admission, and death (aOR 4.90) compared to the wild-type. These findings are not demonstrated by the alpha or beta variants infections within the same cohort.[38] Another study was conducted using Washington Disease Reporting System from December 1, 2020, to July 30, 2021.[39] In this study, the Delta variant also showed a higher hospital admission frequency (HR 2.35). Table 2 summarizes the admission rate and hazard ratio of the Delta variant.[36, 37, 39] When aggregating the hazard ratios presented in the three articles above, the Delta variant had a higher risk of hospital admission than non-Delta variants (HR 2.09, 95% CI: 1.71 to 2.54).

B.1.617.2 does not appear to cause a notably different pattern of symptoms compared to wild-type counterparts, though it does associate with inflammation and severity. An epidemiological study monitoring seven transmission generations with confirmed B.1.617.2 infection in Guangzhou revealed that patients with the Delta variant had lower frequencies of fever, dyspnea, cough, and vomiting compared to wild-type; however, the most common symptoms remained as cough, fever, and sputum production.[40] Patients with B.1.617.2 exhibited a greater inflammatory phenotype reflected in increased leukocytes, neutrophils, and decreased lymphocytes. The Delta patients had a greater proportion of patients < 18 years (16% vs. 3%).[40] Consistent with other findings demonstrating a more severe clinical course, this study also showed that the Delta variant led to a greater proportion of critical infections in the elderly.

Biological studies have demonstrated that Delta variant mutations confer the capability to evade the immune response, mediated significantly by the L452R and T478K residue mutations. L452R and T478K mutations increase intra-chain interactions within the spike protein, which may impede the binding of neutralizing antibodies.[41] L452R, specifically, has been shown by global phylogenetic analysis to be a common mutation across multiple highly proliferative and expanding strains.[35] In recombinant binding assays, L452R/E484Q led to lower mutant recognition from infection-induced antibodies but not vaccination-induced antibodies.[42] The G142D mutation in the spike protein RBD is also a highly preserved mutation in the B.1.617.2 lineage that permits immune evasion, based on a genomic study survey of Delta variant strains.[43] In vitro studies have revealed evasion of both humoral and cell-mediated immunity by B.1.617.2. Sera antibody neutralization studies from vaccinated and previously infected patients show decreased neutralizing activity against the B.1.617.2 variants.[44] A mutated epitope in B.1.617.2 containing L452R, D614G, P681R, T478K, D950N, T19R, E156-, F157-, and R158G led to significantly reduced CD8+ T cell activation from sera.[45]

*Epidemiology and Transmission*

The B.1.617.2 variant is more transmissible across epidemiological and clinical studies. The Delta variant was originally isolated in Maharashtra and West Bengal.[46] Over the period from May to December, the Delta variant shifted from accounting for 0.2% of sequenced infection across all EU countries to 99.6% of sequenced infection.[47] The reproductive number (R0), which represents the average number of secondary contacts infected by an infectious host without epidemiological control efforts, is higher in the Delta variant. Most estimates for the R0 of the ancestral SARS-CoV-2 strains varied between two and four, while the estimates for B.1.617.2 variant R0 varied between 3.2 to 8, with a mean of 5.08.[48, 49] This spread seems to be mediated primarily by person-to-person transmission and in contexts defined by extended close-quarter contact.[48, 50] The secondary attack rate amongst household contacts was estimated to be 25% for vaccinated patients and 38% for unvaccinated patients, as shown in a UK study.[4] In Public Health England's technical briefing from August 6, 2021, the secondary attack rate was 10.4% for households and 6.2% for non-household community transmission, a finding similar to the alpha variant.[51]A stochastic model integrating survey data for K-12 school populations in California found that the Delta variant greatly increased the risk of school transmission compared to the Alpha variant, given school reopening policies.[52] In a study elucidating clinical characteristics of Delta variant infection in Guangzhou, China, viral shedding was detected six days longer from pharyngeal swab samples in the Delta variant compared to the wild-type (14 vs. eight days). Furthermore, it displayed an incubation of four days compared to the six days of wild-type incubation, and viral loads, as measured by cycle thresholds, are higher in the Delta variant.[40] To our knowledge, no systematic epidemiological study has been performed evaluating the nosocomial attack rate of the Delta variant across multiple hospitals, though preliminary case studies of individual hospital outbreaks suggest that the Delta variant is highly transmissible with the potential for breakthrough infection. One study in Israel described a nosocomial outbreak of 42 patients from a single primary case, with an attack rate of 10.6% among healthcare workers and 23.7% among patients, most of whom were vaccinated.[53] Similar outbreaks occurred in Finland and Canada, where they had massive outbreaks of the Delta variant despite personal protective equipment and high vaccination rates.[54, 55]

*Vaccine Efficacy and Breakthrough Infection*

The capacity for B.1.617.2 to evade antibody neutralization from several structural substitutions, as well as several reported outbreaks in highly vaccinated populations, raises concern for a potentially higher rate of breakthrough infection.[44, 53, 54] A UK study found the household secondary attack rate to be 25% for vaccinated individuals.[4] In Israel, the protection rates against COVID-19 decreased to 39% after the emergence of the Delta variant, though protection against hospitalization and severe illness remained at 88% and 91.4%, respectively.[56] In two case-control studies, mRNA-1273 was found to be slightly more effective than the BNT162b2 at preventing any infection, and BNT162b2 was slightly more effective than ChAdOx1 nCoV-19 at preventing symptomatic infection.[57, 58] Furthermore, a single vaccine dose alone provides significantly reduced protection against the Delta variant compared to the alpha variant.[57] Vaccine effectiveness declines with time and waning immunity, specifically from 93% to 53% in after four months, though the decay rate of vaccine effectiveness remains similar to non-Delta variants.[59] A systematic review and meta-analysis extrapolating vaccine efficacy from antibody neutralization titers predicted that the mRNA-1273 and ChAdOx1 nCoV-19 vaccines might be at least 25% less effective for the Delta variant compared to prototype variants.[60] Bian et al. aggregated seven studies from Canada, Scotland, Israel, India, and the UK and found a vaccine efficacy ranging from 59.8% to 87.9% after two doses, whereas the Alpha variant had a vaccine efficacy from 66.1% to 93.4% across the same studies.[56] Although it is possible that the moderate decline in vaccine efficacy resulted from immune escape by B.1.617.2, such findings may also be attributed to waning immunity, relaxation of social distancing policies, and heterogeneity amongst study protocols and geographies.

Although the Delta variant seems to cause breakthrough infection at rates greater than other variants of concern, the severity of these infections are sufficiently attenuated by vaccination. COVID-19-related severe illness during surging Delta periods remain low in vaccinated individuals. Variant-specific data also demonstrate that mRNA and ChAdOx1 nCoV-19 vaccines provide >90% protection against severe illness, while Ad26.COV2.S provides 71% protection. The vaccine efficacies of each vaccine against hospitalization or severe illness from the Delta variant are shown in Table 3.[58, 59, 61-64]

*The Delta variant is compared to the omicron variant.*

On November 24 2021, a noble variant, B.1.1.529, the Omicron variant, emerged in South Africa and is becoming the leading variant around the world. It is analyzed that the Omicron variant is not mutated from the Delta variant, presuming it is derived from other animals and then reinfected in humans.[65] Compared to the Delta variant, it has more mutation residues (43 vs. 18) and higher transmissibility but has lower morbidity and mortality rate.[66] One study from Denmark has calculated the relative reproduction number of the Omicron variant compared to the Delta variant and concluded the rate to be 3.19 (95% CI: 2.82-3.61).[67] Some other studies also calculated the relative reproduction number of the Omicron compared to the Delta variant and estimated the number as 3 to 6.[66] Age of the patients in the Omicron infected group were middle-aged people (vs. Delta variant: children or elderly), and the vaccine efficacy of the Pfizer-BioNTech vaccines were 33%, which is extremely low compared to the Delta variant. The vaccine efficacy of Pfizer-BioNTech vaccines against severe illness and hospitalization was also decreased in the Omicron variant, which is 70% compared to 93% of the Delta variant. People infected with the Delta variant had a 40% relative risk of contracting the Omicron variant, which showed a protective immune response between the variants.[66]

*Current treatment options*

Many drugs were brought up to clinical trials and research, and countless articles have been published. In this review, we have summarized the drugs evidenced by randomized control trials, showing robust evidence. To start with, remdesvir, which was originally targeted for hepatitis C, had showed efficacy median recovery time in hospitalized COVID-19 patients. Taking 200mg loading dose of remdesvir on day 1 and continuing 100mg for 9 additional days has shortened the length of hospital stay from 15 days to 10 days (95% CI 9 to 11 days).[68] Moreover, adding baricitinib with remdesvir showed superiority compared to remdesvir alone.[69] Molnupiravir, a drug originally targeted for influenza virus, which induces lethal mutagenesis and escaping viral proofreading activities, also showed effect reducing the risk of hospitalization or death in unvaccinated adults with COVID-19 (risk difference -6.8 percentage points 95% CI -11.3 to -2.4).[70, 71] Nirmatrelvir/ritonavir, a novel per oral drug made by Pfizer, was approved by United States Food and Drug Administration as emergency use to COVID-19 patients. According to Pfizer, administering this new drug within 3 days has reduced the rate of hospitalization (0.8% in Nirmatrelvir/ritonavir group versus 7% in placebo group) but additional studies are needed.[72] Bamlanivimab/etesevimab also showed efficacy reducing hospitalization or death from any cause in mild to moderate COVID-19 patients (Bamlanivimab/etesevimab 2.1%, placebo 7%, absolute risk difference -4.8 percentage points, 95% CI: -7.4 to -2.3).[73] Dexamethasone, a potent corticosteroid, lowered mortality among the hospitalized COVID-19 patients with mechanical ventilation (age-adjusted rate ratio 0.83, 95% CI: 0.75 to 0.93).[74] Nebulizing interferon beta-1a resulted rapid recovery and greater odds of improvement in COVID-19 patients (odds ratio 2.32, 95% CI: 1.07 to 5.04).[75]

Apart from randomized controlled trials, a decent systematic review and network meta-analysis regarding medication options for COVID-19 was conducted and is currently being updated.[76] According to the study, corticosteroids, and interleukin-6 inhibitors showed meaningful benefit with severe COVID-19 patients.[76] Additionally, janus kinase inhibitor ameliorated the risk and duration of mechanical ventilation but evidence is not robust.

Conclusions

SARS-CoV-2 remains a public health threat in no small part due to evolution into new, highly virulent variants. The Delta variant (B.1.617.2) had emerged as the dominant infection across multiple countries, including the United States and much of Europe. The Delta variant is afforded enhanced viral infectivity and antibody escape from 15 mutations in its Spike protein. These mutations grant this variant a reproductive number approximately twofold that of predecessor variants. The Delta variant is associated with more severe infection, with patients more likely to be hospitalized, require supplemental oxygen, and suffer longer infection course. Case reports suggest that the Delta variant allows for a greater proportion of breakthrough infection against vaccinated individuals, but the rate of serious breakthrough infection is sufficiently attenuated by vaccination across mRNA and vector-based vaccines. Nevertheless, development of a vaccine which could tackle the mutated SARS-CoV-2 is needed.

Table 1. Spike mutations in B.1.617.2 and proposed effects on structure.

|  |  |  |
| --- | --- | --- |
| Spike protein mutation | Genomic position | Structural effects |
| T19R[33] | N-terminal domain | Facilitate immune escape by altering epitopes |
| V70F\*[32] | N-terminal domain | Increase S1/S2 cleavage |
| T95I | N-terminal domain | Unknown |
| G142D[31] | N-terminal domain | Affects side chain conformation in combination with R158G |
| E156del[30] | N-terminal domain | Increase immune escape |
| F157del[30] | N-terminal domain | Increase immune escape |
| R158G[31] | N-terminal domain | Affects side chain conformation in combination with G142D |
| A222V\*[34] | N-terminal domain | Unknown, does not alter antigenicity or viral entry |
| W258L\*[31] | N-terminal domain | Facilitates antibody escape by increasing antibody-epitope distance |
| K417N[27] | S1 subunit RBD | Decrease ACE2 affinity; facilitate immune escape |
| L452R[35] | S1 subunit RBD | Improve ACE2 binding and reduce antibody neutralizing activity |
| T478K[25, 28] | S1 subunit RBD | Increases ACE2 binding by driving a positive electrostatic charge |
| D614G[24] | S1 subunit C-terminal, near furin-cleavage site | Forces the S1 subunit to adopt a more open conformation that readily binds ACE2 |
| P681R[26, 29] | S1 subunit C-terminal, near furin-cleavage site | Enhanced S1/S2 cleavage mediated by enhancing basicity of the poly-basic stretch and facilitation of interaction with furin |
| D950N[33] | S2 subunit, trimer interface | Proposed to affect spike protein dynamics |

**Abbreviations.** RBD, receptor-binding domain

Table 2. Admission rate and hazard ratio of the Delta variant compared to non-delta variant


|  |  |  |  |
| --- | --- | --- | --- |
| Author | Number of  total patients | Number of admitted patients | Adjusted HR\* and 95% CI |
| Twohig et al[36] | Non-Delta: 34,656  Delta: 8,682 | Non-Delta: 764 (2.2%)  Delta: 196 (2.3%) | 2.26 [1.32-3.89] |
| Sheikh et al[37] | Non-Delta: 11,820  Delta: 7,723 | Non-Delta: 243 (2.1%)  Delta: 134 (1.7%) | 1.85 [1.39-2.47] |
| Paredes et al[39] | Non-Delta: 22,068  Delta: 1,934 | Non-Delta: 519 (2.4%)  Delta: 63 (3.3%) | 2.35 [1.72-3.22] |

**Abbreviations.** HR, Hazard Ratio  
\* Hazard ratio for delta variant compared to non-delta variant was estimated using Cox regression

Table 3. Vaccine effectiveness against severe illness or hospitalization from Delta variant infection in vaccinated individuals.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author | Country | Data source | Doses | Vaccine effectiveness against severe illness or hospitalization from Delta variant infection |
| Tang et al.[58] | Qatar | 950,232 | 2 | 93.4% BNT162b2  96.1% mRNA-1273 |
| Bruxvoort et al. [62] | US | 8,153 | 2 | 97.6% mRNA-1273 |
| Chia et al. [63] | Singapore | 218 | 2 | 93% BNT162b2 or mRNA-1273 |
| Tartof et al. [59] | US | 4,920,549 | 2 | 93% BNT162b2 |
| Sheikh et al.[64] | Scotland | 114,706 | 2 | 91% ChAdOx1 nCoV-19  90% BNT162b2 |
| Sisonke study[61] | South Africa | 38,298 | 1 | 71% Ad26.COV2.S |

**Figure 1.** Shared and unique mutations of the Delta and related variants.



**References**

1. Worldometer. COVID Live Update: 437,693,348 Cases and 5,978,017 Deaths from the Coronavirus*.* <https://www.worldometers.info/coronavirus/> [March 1 2022].

2. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 2021; 592: 116-121. DOI: 10.1038/s41586-020-2895-3

3. World Health Organization. Tracking SARS-CoV-2 variants.<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> [November 2 2021].

4. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis* 2021. DOI: 10.1016/s1473-3099(21)00648-4

5. American Society for Microbiology. How Dangerous Is the Delta Variant (B.1.617.2)?<https://asm.org/Articles/2021/July/How-Dangerous-is-the-Delta-Variant-B-1-617-2> [November 2 2021].

6. Kirola L. Genetic emergence of B.1.617.2 in COVID-19. *New Microbes New Infect* 2021; 43: 100929. DOI: 10.1016/j.nmni.2021.100929

7. Hassan W, Kazmi SK, Tahir MJ, et al. Global acceptance and hesitancy of COVID-19 vaccination: A narrative review. *Narra J* 2021; 1.

8. Malik S, Amanda Y, Samsul A, et al. Willingness-to-pay for COVID-19 vaccine in ten low-middle-income countries in Asia, Africa and South America: A cross-sectional study. *Narra J* 2022.

9. NCBI Bookshelf. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)*.* <https://www.ncbi.nlm.nih.gov/books/NBK570580/> [December 20 2021].

10. Rovida F, Cassaniti I, Paolucci S, et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. *Nat Commun* 2021; 12: 6032. DOI: 10.1038/s41467-021-26154-6

11. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* 2021; 27: 1614-1621. DOI: 10.1038/s41591-021-01446-y

12. Vignier N, Bérot V, Bonnave N, et al. Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021. *Emerg Infect Dis* 2021; 27: 2673-2676. DOI: 10.3201/eid2710.211427

13. El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. *Int J Biol Macromol* 2022; 204: 161-168. DOI: 10.1016/j.ijbiomac.2022.01.118

14. Bosch W, Cowart JB, Bhakta S, et al. COVID-19 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida through August 2021. *Clin Infect Dis* 2021. DOI: 10.1093/cid/ciab932

15. Farinholt T, Doddapaneni H, Qin X, et al. Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. *BMC Med* 2021; 19: 255. DOI: 10.1186/s12916-021-02103-4

16. Center for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions*.* <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fvariant-info.html> [December 20 2021].

17. Suratekar R, Ghosh P, Niesen MJM, et al. High diversity in Delta variant across countries revealed via genome-wide analysis of SARS-CoV-2 beyond the Spike protein. *bioRxiv* 2021: 2021.2009.2001.458647. DOI: 10.1101/2021.09.01.458647

18. Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? *Viruses* 2021; 13. DOI: 10.3390/v13071192

19. Tian D, Sun Y, Zhou J, Ye Q. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. *Journal of Medical Virology* 2021; n/a. DOI: <https://doi.org/10.1002/jmv.27376>

20. Fan LQ, Hu XY, Chen YY, et al. Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. *Front Microbiol* 2021; 12: 750725. DOI: 10.3389/fmicb.2021.750725

21. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin* 2020; 41: 1141-1149. DOI: 10.1038/s41401-020-0485-4

22. Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell Mol Immunol* 2020; 17: 613-620. DOI: 10.1038/s41423-020-0400-4

23. Eweas AF, Osman HH, Naguib IA, Abourehab MAS, Abdel-Moneim AS. Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. *Curr Issues Mol Biol* 2022; 44: 3018-3029. DOI: 10.3390/cimb44070208

24. Ozono S, Zhang Y, Ode H, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. *Nat Commun* 2021; 12: 848. DOI: 10.1038/s41467-021-21118-2

25. Pascarella S, Ciccozzi M, Zella D, et al. SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate? *J Med Virol* 2021; 93: 6551-6556. DOI: 10.1002/jmv.27210

26. Cherian S, Potdar V, Jadhav S, et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. *Microorganisms* 2021; 9. DOI: 10.3390/microorganisms9071542

27. Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. *Elife* 2021; 10. DOI: 10.7554/eLife.70658

28. Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. *J Med Virol* 2021; 93: 5638-5643. DOI: 10.1002/jmv.27062

29. Peacock TP, Sheppard CM, Brown JC, et al. The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. *bioRxiv* 2021: 2021.2005.2028.446163. DOI: 10.1101/2021.05.28.446163

30. Chaudhari AM, Kumar D, Joshi M, Patel A, Joshi C. E156/G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.167.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape. *bioRxiv* 2021: 2021.2006.2007.447321. DOI: 10.1101/2021.06.07.447321

31. Kannan SR, Spratt AN, Cohen AR, et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. *J Autoimmun* 2021; 124: 102715. DOI: 10.1016/j.jaut.2021.102715

32. Meng B, Kemp SA, Papa G, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. *Cell Rep* 2021; 35: 109292. DOI: 10.1016/j.celrep.2021.109292

33. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* 2021; 596: 276-280. DOI: 10.1038/s41586-021-03777-9

34. Hodcroft EB, Zuber M, Nadeau S, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *Nature* 2021; 595: 707-712. DOI: 10.1038/s41586-021-03677-y

35. Tchesnokova V, Kulasekara H, Larson L, et al. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. *J Clin Microbiol* 2021; 59: e0092121. DOI: 10.1128/jcm.00921-21

36. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis* 2021. DOI: 10.1016/s1473-3099(21)00475-8

37. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021; 397: 2461-2462. DOI: 10.1016/s0140-6736(21)01358-1

38. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *Clin Infect Dis* 2021. DOI: 10.1093/cid/ciab721

39. Paredes MI, Lunn SM, Famulare M, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. *medRxiv* 2021. DOI: 10.1101/2021.09.29.21264272

40. Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. *EClinicalMedicine* 2021; 40: 101129. DOI: 10.1016/j.eclinm.2021.101129

41. Kumar V, Singh J, Hasnain SE, Sundar D. Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity. *Int J Mol Sci* 2021; 22. DOI: 10.3390/ijms22179131

42. Augusto G, Mohsen MO, Zinkhan S, Liu X, Vogel M, Bachmann MF. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. *Allergy* 2021. DOI: 10.1111/all.15065

43. Shen L, Triche TJ, Bard JD, Biegel JA, Judkins AR, Gai X. Spike Protein NTD mutation G142D in SARS-CoV-2 Delta VOC lineages is associated with frequent back mutations, increased viral loads, and immune evasion. *medRxiv* 2021: 2021.2009.2012.21263475. DOI: 10.1101/2021.09.12.21263475

44. Edara VV, Pinsky BA, Suthar MS, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N Engl J Med* 2021; 385: 664-666. DOI: 10.1056/NEJMc2107799

45. Zhang H, Deng S, Ren L, et al. Profiling CD8(+) T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. *Cell Rep* 2021; 36: 109708. DOI: 10.1016/j.celrep.2021.109708

46. Novelli G, Colona VL, Pandolfi PP. A focus on the spread of the delta variant of SARS-CoV-2 in India. *Indian J Med Res* 2021; 153: 537-541. DOI: 10.4103/ijmr.ijmr\_1353\_21

47. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 16th update*.* <https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-assessing-sars-cov-2-circulation-variants-concern> [December 20 2021].

48. Li H, Burm SW, Hong SH, et al. A Comprehensive Review of Coronavirus Disease 2019: Epidemiology, Transmission, Risk Factors, and International Responses. *Yonsei Med J* 2021; 62: 1-11. DOI: 10.3349/ymj.2021.62.1.1

49. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 2021; 28. DOI: 10.1093/jtm/taab124

50. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis. *JAMA Netw Open* 2022; 5: e229317. DOI: 10.1001/jamanetworkopen.2022.9317

51. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 27, 29 October 2021*.* <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27.pdf>.

52. Head JR, Andrejko KL, Remais JV. Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations. *medRxiv* 2021. DOI: 10.1101/2021.08.20.21262389

53. Shitrit P, Zuckerman NS, Mor O, Gottesman BS, Chowers M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. *Euro Surveill* 2021; 26. DOI: 10.2807/1560-7917.Es.2021.26.39.2100822

54. Hetemäki I, Kääriäinen S, Alho P, et al. An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021. *Euro Surveill* 2021; 26. DOI: 10.2807/1560-7917.Es.2021.26.30.2100636

55. Susky EK, Hota S, Armstrong IE, et al. Hospital outbreak of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant in partially and fully vaccinated patients and healthcare workers in Toronto, Canada. *Infect Control Hosp Epidemiol* 2021: 1-4. DOI: 10.1017/ice.2021.471

56. Bian L, Gao Q, Gao F, et al. Impact of the Delta variant on vaccine efficacy and response strategies. *Expert Rev Vaccines* 2021; 20: 1201-1209. DOI: 10.1080/14760584.2021.1976153

57. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; 385: 585-594. DOI: 10.1056/NEJMoa2108891

58. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 2021; 27: 2136-2143. DOI: 10.1038/s41591-021-01583-4

59. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021; 398: 1407-1416. DOI: 10.1016/s0140-6736(21)02183-8

60. Chen X, Azman AS, Lu W, et al. Prediction of vaccine efficacy of the Delta variant. *medRxiv* 2021. DOI: 10.1101/2021.08.26.21262699

61. Gray G, Bekker L-G. Update on the Janssen®(JNJ) Ad26.COV2.S vaccine*.* <https://sacoronavirus.co.za/wp-content/uploads/2021/08/Sisonke-Provisional-Results-6-August-2021GG2.pdf> [December 20 2021].

62. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. *Bmj* 2021; 375: e068848. DOI: 10.1136/bmj-2021-068848

63. Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. *Clin Microbiol Infect* 2021. DOI: 10.1016/j.cmi.2021.11.010

64. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. *N Engl J Med* 2021; 385: 2195-2197. DOI: 10.1056/NEJMc2113864

65. Sun Y, Lin W, Dong W, Xu J. Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. *J Biosaf Biosecur* 2022; 4: 33-37. DOI: 10.1016/j.jobb.2021.12.001

66. Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. *World J Clin Cases* 2022; 10: 1-11. DOI: 10.12998/wjcc.v10.i1.1

67. Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. *J Med Virol* 2021. DOI: 10.1002/jmv.27560

68. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; 383: 1813-1826. DOI: 10.1056/NEJMoa2007764

69. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* 2021; 384: 795-807. DOI: 10.1056/NEJMoa2031994

70. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2022; 386: 509-520. DOI: 10.1056/NEJMoa2116044

71. Masyeni S, Iqhrammullah M, Frediansyah A, et al. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review. *J Med Virol* 2022; 94: 3006-3016. DOI: 10.1002/jmv.27730

72. Couzin-Frankel J. Antiviral pills could change pandemic's course. *Science* 2021; 374: 799-800. DOI: 10.1126/science.acx9605

73. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med* 2021; 385: 1382-1392. DOI: 10.1056/NEJMoa2102685

74. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; 384: 693-704. DOI: 10.1056/NEJMoa2021436

75. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med* 2021; 9: 196-206. DOI: 10.1016/s2213-2600(20)30511-7

76. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ* 2020; 370: m2980. DOI: 10.1136/bmj.m2980